|
1
|
Chen X, Wu T, Du Z, Kang W, Xu R, Meng F, Liu C, Chen Y, Bao Q, Shen J, You Q, Cao D, Jiang Z, Guo X. Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis. Eur J Med Chem 2024; 265:116080. [PMID: 38142510 DOI: 10.1016/j.ejmech.2023.116080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Revised: 12/18/2023] [Accepted: 12/18/2023] [Indexed: 12/26/2023]
Abstract
Multiple sclerosis (MS) is a neuroinflammatory autoimmune disease and lacks effective therapeutic agents. Dysregulation of transcription mediated by bromodomain and extra-terminal domain (BET) proteins containing two different bromodomains (BD1 and BD2) is an important factor in multiple diseases, including MS. Herein, we identified a series of BD1-biased inhibitors, in which compound 16 showed nanomolar potency for BD1 (Kd = 230 nM) and a 60-fold selectivity for BRD4 BD1 over BD2. The co-crystal structure of BRD4 BD1 with 16 indicated that the hydrogen bond interaction of 16 with BD1-specific Asp145 is important for BD1 selectivity. 16 showed favorable brain distribution in mice and PK properties in rats. 16 was able to inhibit microglia activation and had significant therapeutic effects on EAE mice including improvement of spinal cord inflammatory conditions and demyelination protection. Overall, these results suggest that brain-permeable BD1 inhibitors have the potential to be further investigated as therapeutic agents for MS.
Collapse
Affiliation(s)
- Xuetao Chen
- Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China
| | - Tingting Wu
- Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China
| | - Zhiyan Du
- Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China
| | - Wenjing Kang
- Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China
| | - Rujun Xu
- Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China
| | - Fanying Meng
- Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China
| | - Chihong Liu
- Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China
| | - Yali Chen
- Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China
| | - Qichao Bao
- Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China
| | - Jingkang Shen
- Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China
| | - Qidong You
- Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China
| | - Danyan Cao
- Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China.
| | - Zhengyu Jiang
- Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
| | - Xiaoke Guo
- Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
| |
Collapse
|
|
2
|
Sedenkova KN, Sazonov AS, Vasilenko DA, Andriasov KS, Eremenko MG, Grishin YK, Khvatov EV, Goryashchenko AS, Uvarova VI, Osolodkin DI, Ishmukhametov AA, Averina EB. 3-[ N,N-Bis(sulfonyl)amino]isoxazolines with Spiro-Annulated or 1,2-Annulated Cyclooctane Rings Inhibit Reproduction of Tick-Borne Encephalitis, Yellow Fever, and West Nile Viruses. Int J Mol Sci 2023; 24:10758. [PMID: 37445937 DOI: 10.3390/ijms241310758] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Revised: 06/21/2023] [Accepted: 06/22/2023] [Indexed: 07/15/2023] Open
Abstract
Spirocyclic compounds containing heterocyclic moieties represent promising 3D scaffolds for modern drug design. In the search for novel anti-flaviviral agents, we have obtained a series of 3-[N,N-bis(sulfonyl)amino]isoxazolines containing spiro-annulated cyclooctane rings and assessed their antiviral activity against tick-borne encephalitis (TBEV), yellow fever (YFV), and West Nile (WNV) viruses. The structural analogs of spirocyclic compounds with a single sulfonyl group or 1,2-annulated cyclooctane ring were also investigated. Almost all the studied 3-[N,N-bis(sulfonyl)amino]isoxazolines revealed antiviral activity against TBEV and WNV. The most active against TBEV was spiro-isoxazoline derivative containing p-nitrophenyl groups in the sulfonyl part (EC50 2.0 ± 0.5 μM), while the highest potency against WNV was found for the compounds with lipophilic substituents in sulfonyl moiety, naphtyl being the most favorable one (EC50 1.3 ± 0.5 μM). In summary, two novel scaffolds of anti-flaviviral agents based on N,N-bis(sulfonyl)amino]isoxazoline were proposed, and the compounds of this type demonstrated activity against TBEV and WNV.
Collapse
Affiliation(s)
- Kseniya N Sedenkova
- Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia
| | - Artem S Sazonov
- Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia
| | - Dmitry A Vasilenko
- Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia
| | - Kristian S Andriasov
- Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia
| | - Marina G Eremenko
- Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia
| | - Yuri K Grishin
- Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia
| | - Evgeny V Khvatov
- FSASI "Chumakov FSC R&D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia
| | | | - Victoria I Uvarova
- FSASI "Chumakov FSC R&D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia
| | - Dmitry I Osolodkin
- FSASI "Chumakov FSC R&D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia
- Institute of Translational Medicine and Biotechnology, Sechenov Moscow State Medical University, Moscow 119991, Russia
| | - Aydar A Ishmukhametov
- FSASI "Chumakov FSC R&D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia
- Institute of Translational Medicine and Biotechnology, Sechenov Moscow State Medical University, Moscow 119991, Russia
| | - Elena B Averina
- Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia
| |
Collapse
|
|
3
|
He H, Xie M, Zhang M, Zhang H, Zhu H, Fang Y, Shen Z, Wang R, Zhao Z, Zhu L, Qian X, Li H. Design, synthesis and biological evaluation of potent and selective S1PR1 agonists for the treatment of Ulcerative Colitis. CHINESE J CHEM 2022. [DOI: 10.1002/cjoc.202200392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Huan He
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy East China University of Science & Technology Shanghai 200237 China
| | - Mengting Xie
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy East China University of Science & Technology Shanghai 200237 China
| | - Mengting Zhang
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy East China University of Science & Technology Shanghai 200237 China
| | - Haiqin Zhang
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy East China University of Science & Technology Shanghai 200237 China
| | - Huan Zhu
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy East China University of Science & Technology Shanghai 200237 China
| | - Yuxian Fang
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy East China University of Science & Technology Shanghai 200237 China
| | - Zihao Shen
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy East China University of Science & Technology Shanghai 200237 China
| | - Rui Wang
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy East China University of Science & Technology Shanghai 200237 China
| | - Zhenjiang Zhao
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy East China University of Science & Technology Shanghai 200237 China
| | - Lili Zhu
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy East China University of Science & Technology Shanghai 200237 China
| | - Xuhong Qian
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy East China University of Science & Technology Shanghai 200237 China
- Innovation Center for AI and Drug Discovery (ICAIDD) East China Normal University Shanghai 200062 China
| | - Honglin Li
- Shanghai Key Laboratory of New Drug Design, School of Pharmacy East China University of Science & Technology Shanghai 200237 China
- Innovation Center for AI and Drug Discovery (ICAIDD) East China Normal University Shanghai 200062 China
| |
Collapse
|
|
4
|
Park SJ, Kim J, Kim J, Kim Y, Lee EH, Kim HJ, Kim S, Kim B, Kim R, Choi JW, Park JH, Park KD. Synthesis and Evaluation of Serinolamide Derivatives as Sphingosine-1-Phosphate-1 (S1P 1) Receptor Agonists. MOLECULES (BASEL, SWITZERLAND) 2022; 27:molecules27092818. [PMID: 35566164 PMCID: PMC9101607 DOI: 10.3390/molecules27092818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/04/2022] [Revised: 04/22/2022] [Accepted: 04/26/2022] [Indexed: 11/25/2022]
Abstract
Sphingosine-1-phosphate-1 (S1P1) receptor agonists are well-known drugs for treating multiple sclerosis (MS) caused by autoreactive lymphocytes that attack the myelin sheath. Therefore, an effective therapeutic strategy is to reduce the lymphocytes in the blood by inducing S1P1 receptor internalization. We synthesized serinolamide A, a natural product of the sea, and performed S1P1 receptor internalization assay to evaluate functionally antagonistic S1P1 receptor agonist activity. In order to synthesize derivatives with better efficacy than serinolamide A and B, new derivatives were synthesized by introducing the phenyl ring moiety of fingolimod. Among them, compounds 19 and 21 had superior S1P1 agonistic effects to serinolamide. We also confirmed that compound 19 effectively inhibited lymphocyte outflow in peripheral lymphocyte count (PLC) assay.
Collapse
Affiliation(s)
- Sun Jun Park
- Convergence Research Center for Brain Science, Korea Institute of Science & Technology (KIST), Seoul 02792, Korea; (S.J.P.); (J.K.); (J.K.); (Y.K.); (E.H.L.); (H.J.K.); (S.K.); (B.K.); (R.K.); (J.W.C.)
- Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology, Seoul 02792, Korea
| | - Jushin Kim
- Convergence Research Center for Brain Science, Korea Institute of Science & Technology (KIST), Seoul 02792, Korea; (S.J.P.); (J.K.); (J.K.); (Y.K.); (E.H.L.); (H.J.K.); (S.K.); (B.K.); (R.K.); (J.W.C.)
- Department of Biotechnology, Yonsei University, Seoul 03722, Korea
| | - Jaehwan Kim
- Convergence Research Center for Brain Science, Korea Institute of Science & Technology (KIST), Seoul 02792, Korea; (S.J.P.); (J.K.); (J.K.); (Y.K.); (E.H.L.); (H.J.K.); (S.K.); (B.K.); (R.K.); (J.W.C.)
- Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology, Seoul 02792, Korea
| | - Yoowon Kim
- Convergence Research Center for Brain Science, Korea Institute of Science & Technology (KIST), Seoul 02792, Korea; (S.J.P.); (J.K.); (J.K.); (Y.K.); (E.H.L.); (H.J.K.); (S.K.); (B.K.); (R.K.); (J.W.C.)
- Department of Biotechnology, Yonsei University, Seoul 03722, Korea
| | - Elijah Hwejin Lee
- Convergence Research Center for Brain Science, Korea Institute of Science & Technology (KIST), Seoul 02792, Korea; (S.J.P.); (J.K.); (J.K.); (Y.K.); (E.H.L.); (H.J.K.); (S.K.); (B.K.); (R.K.); (J.W.C.)
- Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology, Seoul 02792, Korea
| | - Hyeon Jeong Kim
- Convergence Research Center for Brain Science, Korea Institute of Science & Technology (KIST), Seoul 02792, Korea; (S.J.P.); (J.K.); (J.K.); (Y.K.); (E.H.L.); (H.J.K.); (S.K.); (B.K.); (R.K.); (J.W.C.)
- Department of Biotechnology, Yonsei University, Seoul 03722, Korea
| | - Siwon Kim
- Convergence Research Center for Brain Science, Korea Institute of Science & Technology (KIST), Seoul 02792, Korea; (S.J.P.); (J.K.); (J.K.); (Y.K.); (E.H.L.); (H.J.K.); (S.K.); (B.K.); (R.K.); (J.W.C.)
| | - Byungeun Kim
- Convergence Research Center for Brain Science, Korea Institute of Science & Technology (KIST), Seoul 02792, Korea; (S.J.P.); (J.K.); (J.K.); (Y.K.); (E.H.L.); (H.J.K.); (S.K.); (B.K.); (R.K.); (J.W.C.)
- Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology, Seoul 02792, Korea
| | - Rium Kim
- Convergence Research Center for Brain Science, Korea Institute of Science & Technology (KIST), Seoul 02792, Korea; (S.J.P.); (J.K.); (J.K.); (Y.K.); (E.H.L.); (H.J.K.); (S.K.); (B.K.); (R.K.); (J.W.C.)
- Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology, Seoul 02792, Korea
| | - Ji Won Choi
- Convergence Research Center for Brain Science, Korea Institute of Science & Technology (KIST), Seoul 02792, Korea; (S.J.P.); (J.K.); (J.K.); (Y.K.); (E.H.L.); (H.J.K.); (S.K.); (B.K.); (R.K.); (J.W.C.)
| | - Jong-Hyun Park
- Convergence Research Center for Brain Science, Korea Institute of Science & Technology (KIST), Seoul 02792, Korea; (S.J.P.); (J.K.); (J.K.); (Y.K.); (E.H.L.); (H.J.K.); (S.K.); (B.K.); (R.K.); (J.W.C.)
- Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology, Seoul 02792, Korea
- Correspondence: (J.-H.P.); (K.D.P.)
| | - Ki Duk Park
- Convergence Research Center for Brain Science, Korea Institute of Science & Technology (KIST), Seoul 02792, Korea; (S.J.P.); (J.K.); (J.K.); (Y.K.); (E.H.L.); (H.J.K.); (S.K.); (B.K.); (R.K.); (J.W.C.)
- Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology, Seoul 02792, Korea
- Correspondence: (J.-H.P.); (K.D.P.)
| |
Collapse
|